Ab Initio Pharma Partners on Grant for Personalised Aerosol Therapy System for next-generation biological therapeutics

Ab Initio are experts in the formulation and characterisation of biologicals. Our labs have capability for routine analysis of proteins, peptides, oligonucleotides and RNA,

Ab Initio Pharma is excited to partner with Associate Professor Tuncay Alan, at Monash University, on a groundbreaking project to develop a personalised aerosol drug therapy system. This initiative, funded by a $398,325 grant from Australia's Economic Accelerator (AEA), aims to enable the inhalation of next-generation biological therapeutics.

The project focuses on delivering complex biologics like proteins and peptides via inhalation, offering new treatments for respiratory conditions like asthma and COPD. This personalised approach will allow for more effective and targeted therapy, maximizing benefits while reducing side effects.

As a leader in complex dosage forms, Ab Initio Pharma brings extensive expertise in inhaled biologics and cGMP manufacturing. Our Sydney-based facilities will support the development of this innovative technology, ensuring it meets the highest quality and safety standards.

This collaboration between Ab Initio and Monash University highlights the power of academia-industry partnerships, turning research into real-world solutions that benefit patients and advance drug delivery innovation.

Stay tuned for more updates on this exciting development in inhaled therapeutics!

For more information, contact Ab Initio Pharma.